Vanguard Group Inc. Raises Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Vanguard Group Inc. boosted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 0.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,562,165 shares of the company’s stock after buying an additional 28,573 shares during the quarter. Vanguard Group Inc. owned approximately 12.01% of Omnicell worth $247,628,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its stake in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after buying an additional 273 shares during the last quarter. Van ECK Associates Corp boosted its position in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after acquiring an additional 315 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after purchasing an additional 355 shares during the period. KBC Group NV increased its position in Omnicell by 60.8% during the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after purchasing an additional 778 shares during the last quarter. Finally, AlphaQuest LLC raised its stake in Omnicell by 307.8% during the fourth quarter. AlphaQuest LLC now owns 3,576 shares of the company’s stock worth $159,000 after purchasing an additional 2,699 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on OMCL. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. JPMorgan Chase & Co. cut their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Wells Fargo & Company decreased their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Benchmark reissued a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Finally, StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Monday, March 24th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $51.00.

Omnicell Stock Performance

Shares of OMCL stock opened at $32.69 on Friday. The firm has a market capitalization of $1.53 billion, a P/E ratio of 121.08, a P/E/G ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The company’s fifty day moving average price is $38.16 and its two-hundred day moving average price is $42.25.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.